Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.

@article{Lichtenstein2011CombinationOG,
  title={Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.},
  author={Gary R. Lichtenstein and Stephan Raoul Targan and Marla Cindy Dubinsky and Jerome I. Rotter and Derren Barken and Fred Princen and Susan N. Carroll and Michelle T Brown and Jordan Stachelski and Emil Chuang and Carol J. Landers and Joanne M. Stempak and Sharat Singh and Mark S. Silverberg},
  journal={Inflammatory bowel diseases},
  year={2011},
  volume={17 12},
  pages={
          2488-96
        }
}
BACKGROUND Treatment of Crohn's disease (CD) with biologics may alter disease progression, leading to fewer disease-related complications, but cost and adverse event profiles often limit their effective use. Tools identifying patients at high risk of complications, who would benefit the most from biologics, would be valuable. Previous studies suggest that biomarkers may aid in determining the course of CD. We aimed to determine if combined serologic immune responses and NOD2 genetic markers are… CONTINUE READING